Source: International Congress 2016 – The future of tyrosin kinase inhibitors



Rating:

Share or cite this content

Citations should be made in the following way:
Jacques Cadranel (Paris, France). The future generations of TKIs. International Congress 2016 – The future of tyrosin kinase inhibitors

Member's Comments

No comment yet.

Related content which might interest you: Re-purposing TKI treatment Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 EGFR TKI in the current clinical practice Source: ERS Research Seminar Year: 2015 From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 New concepts in pulmonary oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=63 Year: 2007 How novel targeted therapies have changed patient outcomes in ALK+ NSCLC Source: International Congress 2015 – Multidisciplinary approaches in the personalized care of the ALK + NSCLC patient Year: 2015 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 Current developments and future directions in COPD Source: Eur Respir Rev, 29 (158) 200289; 10.1183/16000617.0289-2020 Year: 2020